BYM338/bimagrumab

( DrugBank: Bimagrumab / KEGG DRUG: Bimagrumab )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
15	封入体筋炎	1

15. 封入体筋炎

臨床試験数 : 42 / 薬物数 : 33 - (DrugBank : 11) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 123

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01925209 (ClinicalTrials.gov)	September 26, 2013	15/8/2013	Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility ...	A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Dose-finding, Pivotal, ...	Sporadic Inclusion Body Myositis	Drug: BYM338/bimagrumab;Drug: Placebo	Novartis Pharmaceuticals	NULL	Completed	36 Years	85 Years	All	251	Phase 2/Phase 3	United States;Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;Ge ...

First Previous1Next Last